Table 3.

Proportion of patients with documented pretreatment screening for HBV, HCV, and TB testing in the primary analysis testing windows, N (%)

Total N=26,802	HBV*	HCV†	TB**	Composite measure‡
No test	14,778 (55.2)	15,948 (59.5)	16,880 (70.3)	11,858 (44.2)
Complete testing	7,731 (28.8)	10,854 (40.5)	7,117 (29.7)	4,157 (15.5)
Partial testing	4293 (16.0)	-	-	10,787 (40.3)
surface Antigen
or viral load only	3911	-	-	-
core Antibody only	382	-	-	-

^*HBV (Hepatitis B virus): The primary analysis testing window included any test documented prior to the index date. Complete testing was defined as documentation of a HBV surface antigen AND HBV core antibody. If an HBV viral load was documented, this counted as an HBV surface antigen.

^†HCV (Hepatitis C virus): The primary analysis testing window included any test documented prior to the index date. Complete testing was defined as documentation of an HCV antibody or HCV viral load.

^**TB (tuberculosis): The primary analysis testing window included any test documented in the 12 months prior to the index date. Eligible patients N=23,997

^‡Composite measure: This measure assessed whether all appropriate tests were documented; in most cases HBV, HCV, and TB testing, except in the case of B-cell therapies, which did not require TB testing.